stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Operating cash flow
Jazz Pharmaceuticals PLC's operating cash flow for fiscal 2025 was $1.4B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $1.7B. Over the past ten years it has ranged from $531.9M (fiscal 2015) to $1.4B (fiscal 2024); the current reading is higher than 91% of that period. Jazz Pharmaceuticals PLC ranks 4th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.4B | (2.88%) |
| FY2024 | $1.4B | 27.83% |
| FY2023 | $1.1B | (14.15%) |
| FY2022 | $1.3B | 63.39% |
| FY2021 | $778.5M | (13.47%) |
| FY2020 | $899.6M | 15.87% |
| FY2019 | $776.4M | (2.82%) |
| FY2018 | $798.9M | 15.27% |
| FY2017 | $693.1M | 17.00% |
| FY2016 | $592.4M | 11.36% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $506.1M | 21.75% |
| Jun 2026 | $415.7M | 1.84% |
| Mar 2026 | $408.2M | 12.62% |
| Dec 2025 | $362.5M | (23.64%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC | $1.7B |
| EXEL Exelixis, Inc. compare | $1.2B |
| HALO Halozyme Therapeutics, Inc. compare | $898.3M |
| BMRN BioMarin Pharmaceutical Inc. compare | $676.6M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| TECH Bio-Techne Corp compare | $292.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$287.6M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.0M |
| SMMT Summit Therapeutics PLC compare | −$458.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement